Edwin R. Parra

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao et al. · Cancer Discovery · 2015 · 916 citations · Full text

Medicine, Immunology, Oncology +17

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2020 · 828 citations

Medicine, Oncology, Pharmacology +14

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Yinghong Wang, Diana H. Wiesnoski, Beth A. Helmink et al. · Nature Medicine · 2018 · 721 citations

Life Sciences, Immunology, Microbiology +14

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +17